In relation to selective HDAC inhibition, histone deacetylase 6 inhibitors (HDAC6i) have shown promise as anti-cancer agents in pre-clinical studies and are currently under clinical trial investigations as a monotherapy or combinatorial therapy for lymphoproliferative disease, hematologic malignancies and solid tumors [27,28,29,30]. The gene discussed is HDAC6; the disease is cancer.